XenaCare Holdings, Inc. (XCHO.OB) Receives Exclusive License to Market and Distribute an FDA Approved Over the Counter Treatment for Chronic Pain
XenaCare Holdings, Inc. (XCHO.OB), a developer of uniquely positioned nutritional products, mass retail products and products for practitioners, recently announced that the company has received the exclusive U.S. license to market and distribute an FDA approved homeopathic treatment for chronic pain. Chronic pain currently affects more than 50 million people throughout the United States. In 2005, U.S. sales of prescription and non-prescription pain management products totaled more than $20.4 billion. Frank Rizzo, chief executive officer of XenaCare Holdings, stated, “We are extremely enthusiastic about this product, as it represents one of the first non-narcotic treatments for chronic pain. As we…